{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:32:31Z","timestamp":1793248351278,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lung cancer remains a globally burdensome disease with high mortality. While current non-small cell lung cancer (NSCLC) treatments \u2013 surgery, chemotherapy, targeted therapy, and immune checkpoint inhibitor\u2013based immunotherapy \u2013 have modestly improved outcomes, drug resistance and severe side effects limit efficacy, highlighting the urgent need for alternative therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>\n                      This study assessed the therapeutic potential of umbilical cord blood-derived natural killer (UCB-NK) cells in NSCLC via\n                      <jats:italic toggle=\"yes\">in vitro, in vivo<\/jats:italic>\n                      , and clinical analyses.\n                      <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                      cytotoxicity of expanded UCB-NK cells was evaluated against NSCLC cell lines (A549, NCI-H1975) at various effector-to-target (E:T) ratios.\n                      <jats:italic toggle=\"yes\">In vivo<\/jats:italic>\n                      antitumor efficacy was examined in A549-bearing NCG (NOD-Prkdcem26Cd52Il2rgem26Cd22\/Gpt) mice treated with UCB-NK cells combined with IL-2. Additionally, a clinical case series of five NSCLC patients receiving multimodal therapy plus UCB-NK infusions was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                      , expanded UCB-NK cells showed dose-dependent cytotoxicity against NSCLC cell lines, achieving up to 80% tumor cell lysis at E:T ratios of 5:1 and 10:1. In A549-bearing NCG mice, UCB-NK\/IL-2 combination therapy significantly reduced tumor volume by 25.59% and tumor weight by 26.5% compared to IL-2 monotherapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Clinical evaluation of five NSCLC cases receiving multimodal therapy plus UCB-NK infusions demonstrated disease stabilization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>UCB-NK cells hold promise as an alternative therapeutic approach for NSCLC, with the potential to combine with other therapies to improve survival and quality of life. However, large-scale clinical studies are needed to verify safety and optimize treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005014","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:00:52Z","timestamp":1779274852000},"page":"4206-4215","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Umbilical cord blood-derived natural killer cells: in vitro, in vivo, and clinical antitumor activity in non-small cell lung cancer (case series)"],"prefix":"10.1097","volume":"88","author":[{"given":"Zhi lan","family":"Zhang","sequence":"first","affiliation":[{"name":"The School of Pharmacy, North China University of Science and Technology, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, North China University of Science and Technology Affiliated Hospital, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Chen","sequence":"additional","affiliation":[{"name":"The School of Pharmacy, North China University of Science and Technology, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"The School of Pharmacy, North China University of Science and Technology, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Oncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jin","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, North China University of Science and Technology Affiliated Hospital, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao Y.","family":"Yang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"R1-20261029","first-page":"100082","article-title":"Group.Transparency in the reporting of Artificial INtelligence\u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R2-20261029","first-page":"209\u201349","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20261029","doi-asserted-by":"crossref","first-page":"2078\u201392","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20261029","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"R5-20261029","doi-asserted-by":"crossref","first-page":"2371\u201381","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20261029","doi-asserted-by":"crossref","first-page":"12786\u201399","DOI":"10.1002\/jcp.27899","article-title":"microRNA-148a-3p inhibited the proliferation and epithelial-mesenchymal transition progression of non-small-cell lung cancer via modulating Ras\/MAPK\/Erk signaling","volume":"234","author":"Xie","year":"2019","journal-title":"J Cell Physiol"},{"key":"R7-20261029","doi-asserted-by":"crossref","first-page":"1311\u201324","DOI":"10.1159\/000485491","article-title":"MiR-193a-3p is an important tumour suppressor in lung cancer and directly targets KRAS","volume":"44","author":"Fan","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"R8-20261029","doi-asserted-by":"crossref","first-page":"2560\u201369","DOI":"10.1172\/JCI132712","article-title":"Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients","volume":"130","author":"Lin","year":"2020","journal-title":"J Clin Invest"},{"key":"R9-20261029","doi-asserted-by":"crossref","first-page":"85\u2013100","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R10-20261029","doi-asserted-by":"crossref","first-page":"200\u201318","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R11-20261029","doi-asserted-by":"crossref","first-page":"93\u2013101","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"R12-20261029","doi-asserted-by":"crossref","first-page":"274\u201383","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"R13-20261029","first-page":"32\u201342","article-title":"An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood","volume":"24","author":"Nakazawa","year":"2023","journal-title":"Regen Ther"},{"key":"R14-20261029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2015.00230","article-title":"Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies","volume":"6","author":"Pittari","year":"2015","journal-title":"Front Immunol"},{"key":"R15-20261029","doi-asserted-by":"crossref","first-page":"331\u201341","DOI":"10.1007\/s00281-018-0685-x","article-title":"Activating and inhibitory receptors expressed on innate lymphoid cells","volume":"40","author":"Guia","year":"2018","journal-title":"Semin Immunopathol"},{"key":"R16-20261029","doi-asserted-by":"crossref","first-page":"3760\u201369","DOI":"10.1097\/JS9.0000000000000940","article-title":"Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines","volume":"109","author":"Mathew","year":"2023","journal-title":"Int J Surg"},{"key":"R17-20261029","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cancers14030843","article-title":"Natural killer cell-mediated immunotherapy for Leukemia","volume":"14","author":"Allison","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R18-20261029","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1038\/s41598-017-08483-z","article-title":"Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK\/Erk signaling inhibition","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"R19-20261029","doi-asserted-by":"crossref","first-page":"1831\u201344","DOI":"10.1080\/15548627.2018.1489946","article-title":"Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy","volume":"14","author":"Yao","year":"2018","journal-title":"Autophagy"},{"key":"R20-20261029","first-page":"91\u2013128","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol"},{"key":"R21-20261029","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R22-20261029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R23-20261029","doi-asserted-by":"crossref","first-page":"924\u201340","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"R24-20261029","doi-asserted-by":"crossref","first-page":"189024","DOI":"10.1016\/j.bbcan.2023.189024","article-title":"Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?","volume":"1878","author":"Gieleci\u0144ska","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R25-20261029","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R26-20261029","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"R27-20261029","doi-asserted-by":"crossref","first-page":"358","DOI":"10.21037\/atm-22-4444","article-title":"Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review","volume":"11","author":"Li","year":"2023","journal-title":"Ann Transl Med"},{"key":"R28-20261029","doi-asserted-by":"crossref","first-page":"1823\u201333","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-20261029","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann Transl Med"},{"key":"R30-20261029","doi-asserted-by":"crossref","first-page":"1422\u201337","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov"},{"key":"R31-20261029","doi-asserted-by":"crossref","first-page":"4654\u201368","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"R32-20261029","doi-asserted-by":"crossref","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 blockade enhances anti-tumor efficacy of NK cells","volume":"7","author":"Oyer","year":"2018","journal-title":"Oncoimmunology"},{"key":"R33-20261029","doi-asserted-by":"crossref","first-page":"209\u201315","DOI":"10.1016\/j.lungcan.2012.12.026","article-title":"CD4\/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy","volume":"80","author":"Hald","year":"2013","journal-title":"Lung Cancer"},{"key":"R34-20261029","doi-asserted-by":"crossref","first-page":"695\u2013704","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8(+) T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol"},{"key":"R35-20261029","doi-asserted-by":"crossref","first-page":"359\u201388","DOI":"10.1615\/CritRevImmunol.2014010604","article-title":"NK cells and their ability to modulate T cells during virus infections","volume":"34","author":"Cook","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"R36-20261029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2016.00251","article-title":"Recognition and Regulation of T Cells by NK Cells","volume":"7","author":"Pallmer","year":"2016","journal-title":"Front Immunol"},{"key":"R37-20261029","doi-asserted-by":"crossref","first-page":"1474\u201380","DOI":"10.1200\/JCO.1988.6.9.1474","article-title":"Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis","volume":"6","author":"S\u00f8rensen","year":"1988","journal-title":"J Clin Oncol"},{"key":"R38-20261029","doi-asserted-by":"crossref","first-page":"419\u201325","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"key":"R39-20261029","doi-asserted-by":"crossref","first-page":"e112397","DOI":"10.1371\/journal.pone.0112397","article-title":"Low dose cranial irradiation-induced cerebrovascular damage is reversible in mice","volume":"9","author":"S\u00e1ndor","year":"2014","journal-title":"PLoS One"},{"key":"R40-20261029","first-page":"1\u20136","article-title":"Overview and introduction: the blood-brain barrier in health and disease","volume":"53 Suppl 6","author":"Abbott","year":"2012","journal-title":"Epilepsia"},{"key":"R41-20261029","doi-asserted-by":"crossref","first-page":"1500\u201313","DOI":"10.1038\/jcbfm.2013.135","article-title":"Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease","volume":"33","author":"Erickson","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"R42-20261029","first-page":"683\u201388","article-title":"Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)","volume":"9","author":"van Vulpen","year":"2002","journal-title":"Oncol Rep"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:01:02Z","timestamp":1793246462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005014","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2025-10-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}